Purpose: To systematically compare outcomes between antibiotic classes in treating outpatient community-acquired pneumonia, regarding antibacterials active against atypical organisms, or various antibacterial classes with similar atypical coverage. Methods: Meta-analysis of randomized control trials of antibacterials for community-acquired pneumonia in outpatients at least 18 years old. Studies were independently reviewed two reviewers. We compared clinical success and mortality between different oral antibiotic classes and specifically compared antibacterials with atypical coverage (macrolides and fluoroquinolones) with others. Results: Thirteen eligible studies involving 4,314 total patients were included. The quality of the studies was ...
BACKGROUND: Emergency physicians are under pressure to prescribe an antibiotic early in the treatmen...
Background: There is much controversy about the ideal approach to the management of community acquir...
Background: We compared beta-lactam-macrolide (combination) therapy vs. beta-lactam alone (monothera...
BACKGROUND: For years, monotherapy with a beta-lactam antibiotic (penicillin, amoxicillin or second-...
BACKGROUND: For years, monotherapy with a beta-lactam antibiotic (penicillin, amoxicillin or second-...
Background: The questions of whether the use of antibiotics that are active against atypical organis...
Background: We aimed to review relevant randomized controlled trials to assess the relative clinical...
The benefit of empiric coverage for community-acquired pneumonia (CAP) for atypical bacteria is cont...
BACKGROUND: Lower respiratory tract infection (LRTI) is the third leading cause of death worldwide a...
ABSTRACT: Objectives: The increasing epidemic of infections caused by drug-resistant Gram-negative ...
At the time of diagnosis in patients with community-acquired pneumonia, the causative pathogen is ra...
Background: Community-acquired pneumonia (CAP) has a potential complication of bacteremia. The objec...
To determine patterns and predictors of antimicrobial drug use for outpatients with community-acquir...
Objectives: This meta-analysis examined the effect of macrolides on resolution of community-acquired...
Background: Both typical and atypical bacteria can cause community-acquired pneumonia (CAP); however...
BACKGROUND: Emergency physicians are under pressure to prescribe an antibiotic early in the treatmen...
Background: There is much controversy about the ideal approach to the management of community acquir...
Background: We compared beta-lactam-macrolide (combination) therapy vs. beta-lactam alone (monothera...
BACKGROUND: For years, monotherapy with a beta-lactam antibiotic (penicillin, amoxicillin or second-...
BACKGROUND: For years, monotherapy with a beta-lactam antibiotic (penicillin, amoxicillin or second-...
Background: The questions of whether the use of antibiotics that are active against atypical organis...
Background: We aimed to review relevant randomized controlled trials to assess the relative clinical...
The benefit of empiric coverage for community-acquired pneumonia (CAP) for atypical bacteria is cont...
BACKGROUND: Lower respiratory tract infection (LRTI) is the third leading cause of death worldwide a...
ABSTRACT: Objectives: The increasing epidemic of infections caused by drug-resistant Gram-negative ...
At the time of diagnosis in patients with community-acquired pneumonia, the causative pathogen is ra...
Background: Community-acquired pneumonia (CAP) has a potential complication of bacteremia. The objec...
To determine patterns and predictors of antimicrobial drug use for outpatients with community-acquir...
Objectives: This meta-analysis examined the effect of macrolides on resolution of community-acquired...
Background: Both typical and atypical bacteria can cause community-acquired pneumonia (CAP); however...
BACKGROUND: Emergency physicians are under pressure to prescribe an antibiotic early in the treatmen...
Background: There is much controversy about the ideal approach to the management of community acquir...
Background: We compared beta-lactam-macrolide (combination) therapy vs. beta-lactam alone (monothera...